Merck's Sac-TMT improves overall survival in Phase 3 advanced gastroesophageal cancer trial
MRK•Merck's sacituzumab tirumotecan improved overall survival versus physician-selected treatment in the Phase 3 TroFuse-015 trial, meeting its primary endpoint. It did not meet the secondary endpoint of progression-free survival, and no new safety signals emerged.




